In Vitro Inhibition of Helicobacter pylori Growth by Redox Cycling Phenylaminojuglones
Author
dc.contributor.author
Benites, Julio
Author
dc.contributor.author
Toledo, Héctor
Author
dc.contributor.author
Salas, Felipe
Author
dc.contributor.author
Guerrero, Angélica
Author
dc.contributor.author
Rios, David
Author
dc.contributor.author
Valderrama, Jaime A.
Author
dc.contributor.author
Calderon, Pedro Buc
Admission date
dc.date.accessioned
2019-03-18T12:03:49Z
Available date
dc.date.available
2019-03-18T12:03:49Z
Publication date
dc.date.issued
2018
Cita de ítem
dc.identifier.citation
Oxidative medicine and cellular longevity, Volumen 2018,
Identifier
dc.identifier.issn
19420994
Identifier
dc.identifier.other
10.1155/2018/1618051
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/167676
Abstract
dc.description.abstract
Infection by Helicobacter pylori increases 10 times the risk of developing gastric cancer. Juglone, a natural occurring 1,4-naphthoquinone, prevents H. pylori growth by interfering with some of its critical metabolic pathways. Here, we report the design, synthesis, and in vitro evaluation of a series of juglone derivatives, namely, 2/3-phenylaminojuglones, as potential H. pylori growth inhibitors. Results show that 5 out of 12 phenylaminojuglones (at 1.5 μg/mL) were 1.5-2.2-fold more active than juglone. Interestingly, most of the phenylaminojuglones (10 out of 12) were 1.1-2.8 fold more active than metronidazole, a known H. pylori growth inhibitor. The most active compound, namely, 2-((3,4,5-trimethoxyphenyl)amino)-5-hydroxynaphthalene-1,4-dione 7, showed significant higher halo of growth inhibitions (HGI = 32.25 mm) to that of juglone and metronidazole (HGI = 14.50 and 11.67 mm). Structural activity relationships of the series suggest that the nature and location of the nitrogen subs